https://scholars.lib.ntu.edu.tw/handle/123456789/494956
標題: | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 | 作者: | Wu Y.-L Sequist L.V Hu C.-P Feng J Lu S Huang Y Li W Hou M Schuler M Mok T Yamamoto N O'Byrne K Hirsh V Gibson N Massey D Kim M CHIH-HSIN YANG |
關鍵字: | afatinib; circulating cell-free DNA; EGFR mutation; ERBB family blocker; non-small cell lung cancer | 公開日期: | 2017 | 出版社: | Nature Publishing Group | 卷: | 116 | 期: | 2 | 起(迄)頁: | 175-185 | 來源出版物: | British Journal of Cancer | 摘要: | Background:In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and prognostic and predictive utility of cfDNA positivity (cfDNA+).Methods:Paired tumour and blood samples were prospectively collected from randomised patients. Mutations were detected using cfDNA from serum (LL3) or plasma (LL6) by a validated allele-specific quantitative real-Time PCR kit.Results:EGFR mutation detection rates in cfDNA were 28.6% (serum) and 60.5% (plasma). Mutation detection in blood was associated with advanced disease characteristics, including higher performance score, number of metastatic sites and bone/liver metastases, and poorer prognosis. In patients with common EGFR mutations, afatinib improved progression-free survival vs chemotherapy in cfDNA+ (LL3: HR, 0.35; P=0.0009; LL6: HR, 0.25; P<0.0001) and cfDNA-(LL3: HR, 0.46; P<0.0001; LL6: HR, 0.12; P<0.0001) cohorts. A trend towards overall survival benefit with afatinib was observed in cfDNA+ patients.Conclusions:Plasma cfDNA is a promising alternative to biopsy for EGFR testing. Detectable mutation in blood was associated with more advanced disease and poorer prognosis. Afatinib improved outcomes in EGFR mutation-positive patients regardless of blood mutation status. ? The Author(s) named above. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007270680&doi=10.1038%2fbjc.2016.420&partnerID=40&md5=8c17099b9a0367d51370c588838532bd https://scholars.lib.ntu.edu.tw/handle/123456789/494956 |
ISSN: | 0007-0920 | DOI: | 10.1038/bjc.2016.420 | SDG/關鍵字: | afatinib; cisplatin; DNA; epidermal growth factor receptor; gemcitabine; pemetrexed; afatinib; antineoplastic agent; DNA; EGFR protein, human; epidermal growth factor receptor; quinazoline derivative; adult; aged; allele; Article; blood sampling; bone metastasis; cancer combination chemotherapy; cancer patient; cancer prognosis; cancer survival; clinical evaluation; controlled study; female; human; liver metastasis; lung adenocarcinoma; major clinical study; male; multiple cycle treatment; outcome assessment; overall survival; phase 3 clinical trial; priority journal; progression free survival; randomized controlled trial; real time polymerase chain reaction; adenocarcinoma; blood; blood analysis; clinical trial; dna mutational analysis; feasibility study; genetics; Lung Neoplasms; middle aged; mortality; multicenter study; predictive value; procedures; prognosis; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; DNA Mutational Analysis; DNA, Neoplasm; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, Epidermal Growth Factor |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。